Atherosclerosis Therapeutics Market Size Expected to Grow by USD 3.44 Billion | Increase risk factors for atherosclerosis to stimulate growth

NEW YORK, April 11, 2022 /PRNewswire/ — Market share for atherosclerosis treatments is expected to increase by $3.44 billion from 2021 to 2026, growing at a CAGR of 5.66% over the forecast period, according to Technavio. The report offers up-to-date analysis along with the exact growth variance and annual growth rate.

Technavio has announced its latest market research report titled Atherosclerosis Therapeutics Market by Product and Geography – Forecast and Analysis 2022-2026

Request a free sample report for additional market-related information and to understand market dynamics

Atherosclerosis Therapeutics Market 2022-2026: Scope

The Atherosclerosis Therapeutics market report covers the following areas:

Atherosclerosis Therapeutics Market 2022-2026: Driver and Challenge

the increased risk factors for atherosclerosis are driving the growth of the atherosclerosis therapeutics market. According to the NIH, high cholesterol affects one in 500 people in most countries. Factors such as smoking, poor dietary habits, sleep deprivation and lack of physical activities can lead to an increased risk of atherosclerosis. This, in turn, drives the demand for atherosclerosis treatments, thereby contributing to the growth of the market.

Side effects associated with atherosclerosis treatments are challenging the growth of the atherosclerosis therapeutics market. For example, ZOCOR works by lowering LDL cholesterol levels in the blood. However, according to several research studies, the drug can cause muscle diseases, such as myopathy and rhabdomyolysis. Therefore, the powerful side effects of atherosclerosis treatments are negatively affecting the market growth.

Atherosclerosis Therapeutics Market 2022-2026: Segmentation

By product, the market has been segmented into small molecules and biologics. the small molecule segment will experience significant growth in its market share over the forecast period. The use of small molecules can significantly reduce the risk of complications associated with atherosclerosis. Additionally, the manufacturing and regulatory approval process for small molecules is relatively straightforward. Hence, new players in the market are responding to the growing demand for small molecule drugs.

By geography, the market has been segmented into North America, Europe, Asiaand Rest of the World (ROW). North America will experience significant growth in its market share over the forecast period.

Learn more about the contribution of each market segment. Download a free sample report

Atherosclerosis Therapeutics Market 2022-2026: Vendor Analysis

We provide detailed analysis of around 25 vendors operating in the Atherosclerosis Therapeutics market including Amgen Inc., AstraZeneca Plc, Dr. Reddys Laboratories Ltd., Eli Lilly and Co., F. Hoffmann La Roche Ltd. , Ionis Pharmaceuticals Inc., Merck and Co. Inc., Novartis AG, Regeneron Pharmaceuticals Inc., Sanofi SA, Viatris Inc., GlaxoSmithKline Plc and Pfizer Inc., among others.

Atherosclerosis Therapeutics Market 2022-2026: Key Highlights

  • Market CAGR over the forecast period 2022-2026

  • In-depth information on the factors that will contribute to the growth of the Atherosclerosis Treatments Market over the next five years

  • Estimation of the Atherosclerosis Therapeutics market size and its contribution to the parent market

  • Predictions on upcoming trends and changes in consumer behavior

  • The growth of the atherosclerosis therapeutics market

  • Market Competitive Landscape Analysis and Detailed Vendor Information

  • Comprehensive details of factors that will challenge the growth of the Atherosclerosis Therapeutics Market vendors

Related reports:

Plasma Therapeutics Market by Product and Geography – Forecast and Analysis 2022-2026

Gene Therapy Market by Therapy Area and Geography – Forecast and Analysis 2022-2026

Atherosclerosis Therapeutics Market Scope

Report cover

Details

Page number

120

base year

2021

Forecast period

2022-2026

Growth momentum and CAGR

Accelerate at a CAGR of 5.66%

Market Growth 2022-2026

$3.44 billion

Market structure

Concentrate

Annual growth (%)

5.13

Regional analysis

North America, Europe, Asia and Rest of the World (ROW)

Successful market contribution

North America at 44%

Main consumer countries

USA, Canada, UK, Germany and China

Competitive landscape

Leading companies, competitive strategies, scope of consumer engagement

Profiled companies

Amgen Inc., AstraZeneca Plc, Dr. Reddys Laboratories Ltd., Eli Lilly and Co., F. Hoffmann La Roche Ltd., Ionis Pharmaceuticals Inc., Merck and Co. Inc., Novartis AG, Regeneron Pharmaceuticals Inc., Sanofi SA , Viatris Inc., GlaxoSmithKline Plc and Pfizer Inc.

Market dynamics

Parent Market Analysis, Market Growth Drivers and Barriers, Fast and Slow Growing Segment Analysis, COVID 19 Impact and Future Consumer Dynamics, Market Condition Analysis for the Forecast Period,

Personalization area

If our report does not include the data you are looking for, you can contact our analysts and customize the segments.

Contents :

1. Summary

2 Market landscape

3 Market sizing

4 Five forces analysis

5 Market Segmentation by Product

6 Customer Landscape

7 Geographic landscape

8 drivers, challenges and trends

9 Supplier landscape

10 Vendor Analysis

11 Appendix

About Us

Technavio is a global leader in technology research and consulting. Their research and analysis focuses on emerging market trends and provides actionable insights to help companies identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialist analysts, Technavio’s reporting library consists of over 17,000 reports and counts, spanning 800 technologies, spanning 50 countries. Their customer base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing customer base relies on Technavio’s comprehensive coverage, in-depth research, and actionable market intelligence to identify opportunities in existing markets and potentials and assess their competitive positions in changing market scenarios.

Contact

Technavio Research
Jesse Maida
Media & Marketing Manager
USA: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com/

Technavio (PRNewsfoto/Technavio)

Technavio (PRNewsfoto/Technavio)

Quote

Quote

See original content to download multimedia: https://www.prnewswire.com/news-releases/atherosclerosis-therapeutics-market-size-to-grow-by-usd-3-44-billion–increasing-risk- factors-for-atherosclerosis-to-boost-growth–technavio-301521006.html

SOURCETechnavio

About Myra R.

Check Also

Fed set for another 75 basis point rate hike; unlikely early pivot

A woman holds US dollar banknotes in this illustration taken May 30, 2022. REUTERS/Dado Ruvic/Illustration …